Telehealth company Hims & Hers Health (NYSE:HIMS) announced better-than-expected revenue in Q1 CY2025, with sales up 111% year on year to $586 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $540 million was less impressive, coming in 2.4% below expectations. Its non-GAAP profit of $0.30 per share was 32.2% above analysts’ consensus estimates.

Is now the time to buy HIMS? Find out in our full research report (it’s free).

  • Revenue: $586 million vs analyst estimates of $541.3 million (111% year-on-year growth, 8.3% beat)

  • Adjusted EPS: $0.30 vs analyst estimates of $0.23 (32.2% beat)

  • Adjusted EBITDA: $91.06 million vs analyst estimates of $61.78 million (15.5% margin, 47.4% beat)

  • The company reconfirmed its revenue guidance for the full year of $2.35 billion at the midpoint

  • EBITDA guidance for the full year is $315 million at the midpoint, above analyst estimates of $296.5 million

  • Operating Margin: 9.9%, up from 3.6% in the same quarter last year

  • Free Cash Flow Margin: 8.5%, up from 4.3% in the same quarter last year

  • Customers: 2.37 million, up from 2.23 million in the previous quarter

  • Market Capitalization: $9.37 billion

Hims & Hers Health’s Q1 results reflected significant expansion in personalized healthcare offerings and strong subscriber growth, both of which management cited as key contributors to revenue and margin outperformance. CEO Andrew Dudum highlighted the company’s evolution, stating, “We are scaling a platform for the future of healthcare—one that’s accessible, affordable, transparent, and personalized,” and pointed to momentum in dermatology, sexual health, and weight loss as critical success factors this quarter.

Looking ahead, management maintained a positive outlook for the full year while acknowledging short-term headwinds tied to product mix shifts and transitions in the weight loss category. CFO Yemi Okupe noted that the company’s guidance assumes continued robust growth in tenured specialties but flagged volatility in sexual health as the subscriber base moves toward higher-retention, premium daily solutions. Management attributed long-term confidence to strategic investments in partnerships, automation, and new specialty launches.

Hims & Hers Health leadership discussed multiple operational and strategic drivers affecting the quarter’s results, with particular focus on the rapid adoption of personalized treatments and the impact of new partnerships on future growth.